NasdaqGS - Nasdaq Real Time Price USD

Cullinan Therapeutics, Inc. (CGEM)

23.03

-1.10

(-4.56%)

At close: 4:00 PM EDT

23.49

+0.46

(+2.00%)

After hours: 4:51 PM EDT

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer and Jeffrey Jones, MD, MBA, Chief Medical Officer, will participate in a fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA, being held virtually on May 28 and 29, 2024. The fireside chat is scheduled for Wednesday, M

GlobeNewswire 4 days ago

CGEM
-4.56%
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

One of the hallmarks of cancer is the ability to avoid detection by the immune system. Cancer cells get selected for escape mechanisms that can render them invisible to immune cells. The resulting immune evasion enables tumor growth and metastasis. There is a significant unmet need for novel therapies that can help overcome immune evasion mechanisms employed by tumors. CLN-619 is a potential first-in-class humanized lgG1 monoclonal antibody that binds to the stress induced ligands MICA and MICB,

GlobeNewswire 5 days ago

CGEM
-4.56%
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at ASCO 2024 Annual Meeting CLN-978 development to focus exclusively on autoimmune diseases, starting with systemic lupus erythematosus (SLE) as the first indication Cash and investments of $434.8 million as of March 31, 2024, plus gross proceeds of $280 million from April private placement extends cash runway into 2028 Company appoints David Meek to its Board of Directors CAMBRIDGE, Mass

GlobeNewswire 13 days ago

CGEM
-4.56%
Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ...

Jennifer Michaelson, Chief Scientific Officer at Cullinan Therapeutics Inc (NASDAQ:CGEM), sold 63,606 shares of the company on May 7, 2024.

GuruFocus.com 19 days ago

CGEM
-4.56%
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment of Mary Kay Fenton as Chief Financial Officer, beginning April 29. “I am pleased to welcome Mary Kay to Cullinan Therapeutics as Chief Financial Officer. This is a pivotal time for Cullinan as we expand into autoimmune diseases and continue to advance our clinical-stage oncology portfolio,” sa

GlobeNewswire 29 days ago

CGEM
-4.56%
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?

A recent academic case study, published on April 22, examined using Amgen Inc’s (NASDAQ:AMGN) Blincyto, a bispecific CD3xCD19 T-cell engager, to treat a patient with severe systemic sclerosis. The findings have implications for Cullinan Therapeutics Inc’s (NASDAQ:CGEM) CLN-978, a similar CD19xCD3 bispecific T-cell engager. Most recently, Cullinan Therapeutics, formerly Cullinan Oncology, announced its plans to expand into autoimmune diseases and intends to pursue the development of CLN-978 in au

Benzinga last month

CGEM
-4.56%
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid tumors will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31-June 4, 2024. The data will include first results from the dose escalation cohort of CLN-619

GlobeNewswire last month

CGEM
-4.56%
Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity

Cullinan Therapeutics Inc (NASDAQ:CGEM), formerly Cullinan Oncology Inc, announced its plans to expand into autoimmune diseases and intends to pursue the development of CLN-978 in autoimmune diseases, with systemic lupus erythematosus (SLE) as a first indication. In SLE, the immune system of the body mistakenly attacks healthy tissue. The company believes that CLN-978 has the potential to be a first-in-class, off-the-shelf, disease-modifying treatment in autoimmune diseases with a differentiated

Benzinga last month

CGEM
-4.56%
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication Clinical observations from CLN-978 B-NHL study show rapid, deep, and sustained B cell depletion and clinical activity Corporate name change to Cullinan Therapeutics reflects strategic expansion into autoimmune diseases Cullinan Therapeutics to host a virtual investor event taking place on April 16 at 8:00 am ET CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) --

GlobeNewswire last month

CGEM
-4.56%
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

Financing includes new and existing leading life sciences institutional investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 Cullinan to host a virtual investor event on April 16 at 8:00 am ET CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (formerly Cullinan Oncology, Inc.) (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced

GlobeNewswire last month

CGEM
-4.56%
Cullinan changes name, pivots to autoimmune disease

The biotech says a dual-pronged antibody it’s developing could become an “off-the-shelf” alternative to cell therapies in development for lupus and other inflammatory conditions.

BioPharma Dive last month

CGEM
-4.56%
Cullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial Results

Strategic Developments and Financial Highlights Reflect Progress and Growth

GuruFocus.com 2 months ago

CGEM
-4.56%
Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Simply Wall St. 2 months ago

CGEM
-4.56%
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Cullinan remains on track to report additional solid tumor dose escalation data for CLN-619 in the second quarter of 2024 and recently received FDA clearance for an IND to evaluate CLN-619 in relapsed/refractory multiple myeloma The company is exploring development of its CD19xCD3 T cell engager CLN-978 in autoimmune disorders Cash and investments of $468.3 million as of December 31, 2023 continues to provide runway into the second half of 2026 CAMBRIDGE, Mass., March 14, 2024 (GLOBE NEWSWIRE) -

GlobeNewswire 2 months ago

CGEM
-4.56%
$Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma$
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

Company will initiate Phase 1 study of CLN-619 for relapsed or refractory multiple myeloma, first MICA/B antibody clinical study in hematologic malignancies Follows ongoing clinical study of CLN-619 alone and in combination with pembrolizumab in solid tumors, with anticipated updated clinical data in Q2 2024 CAMBRIDGE, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today annou

GlobeNewswire 2 months ago

CGEM
-4.56%
Cullinan Oncology to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced its participation in the following upcoming investor conferences: Jeffrey Jones, M.D., M.P.H., M.B.A., Chief Medical Officer, will participate in a Panel Discussion on Gynecologic Cancers at the TD Cowen 44th Annual Health Care Conference in Boston, MA on Tuesday, March 5, 2024, at 10

GlobeNewswire 2 months ago

CGEM
-4.56%
13 Best Booming Stocks to Buy Right Now

In this article, we will take a detailed look at the 13 Best Booming Stocks to Buy Right Now. For a quick overview of such stocks, read our article 5 Best Booming Stocks to Buy Right Now. Despite latest data showing elevated inflation and a decline in retail sales, some major investment firms are looking beyond the short-term market […]

Insider Monkey 3 months ago

OSCR

FATE

VKTX
Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc

Corrine Savill, Chief Business Officer of Cullinan Oncology Inc (NASDAQ:CGEM), has sold 40,000 shares of the company on February 1, 2024, according to a recent SEC Filing.

GuruFocus.com 3 months ago

CGEM
-4.56%
Insider Sell: Cullinan Oncology Inc's Chief Business Officer Corrine Savill Sold 40,000 Shares

Cullinan Oncology Inc (NASDAQ:CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology treatments, has reported an insider sell according to a recent SEC filing.

GuruFocus.com 4 months ago

CGEM
-4.56%
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that Chief Executive Officer, Nadim Ahmed, will present at the 42nd Annual J.P. Morgan Healthcare Conference, being held January 8-11, 2024 in San Francisco, CA. Mr. Ahmed’s presentation is scheduled for Thursday, January 11, at 10:30 am PST (1:30 pm EST). A live webcast of the presen

GlobeNewswire 5 months ago

CGEM
-4.56%

Performance Overview

Return	CGEM	S&P 500
YTD	+126.01%	+11.24%
1-Year	+129.15%	+26.17%
3-Year	-23.46%	+26.31%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Cullinan Therapeutics, Inc. (CGEM)

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ...

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

Cullinan changes name, pivots to autoimmune disease

Cullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial Results

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

Cullinan Oncology to Participate in Upcoming Investor Conferences

13 Best Booming Stocks to Buy Right Now

Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc

Insider Sell: Cullinan Oncology Inc's Chief Business Officer Corrine Savill Sold 40,000 Shares

Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Performance Overview